John Lahaye, Member Business Advisory Board, Business Development CRO economic segment
Roles at LPBI Group:
- Advise the LPBI Group Board on all phases of the Exit process
- Advise the LPBI Group Board on all matters of M&A activities
- Focus efforts on prospecting for a Strategic Potential Acquirer (SPA) for LPBI Group’s Portfolio of Ten Digital Intellectual Property Assets, See https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/
- Activate existing contacts in the CRO economic segment
- Focus efforts on top seven CRO players
- Develop marketing communication materials based on LPBI Group existing documentation for reaching out to top players in the CRO economic segment
- Adjust marketing communication materials based on LPBI Group existing documentation for reaching out to top players in the Diagnostics and Big Pharma economic segments after exhaustion of the CRO economic segment if deemed appropriate
- As a potential transaction surfaces: act proactively to develop all the relations needed to move the negotiation from exploration to proposals to MOU to contract negotiation and DEAL closure. Follow up on credit transfer(s) and monitor clearance of proceeds to all parties involved as recorded on the contract(s)
- Monitor and record on PERSONAL PAGE all External communications using date, only initials for Name, full record of function(s) in the organization and Pending follow up activity See https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/john-lahaye-member-business-advisory-board-business-development-cro-economic-segment-personal-page/
- Attend all the Monthly Global LPBI Group Board Meeting for 2024, as listed in Calendar of Zooms https://pharmaceuticalintelligence.com/2-0-lpbi-calendar-of-zooms/
- Provide Monthly Report to the Board on the Board Meeting dates on the Calendar of Zooms in the Business Side session of the monthly meetings
- Consult directly with LPBI Group’s Founder and other members of the Board as deemed appropriate
- All External presentations about LPBI Group’s Portfolio of Ten Digital Intellectual Property Assets need to be known to the Founder
The following 12 Categories of Research in LPBI Group’s Journal ontology represent the declared domains of expertise [the order of listing does not imply cardinality]
- Big Data Intelligent Information Systems
- Commercialization
- Conference Coverage with Social Media
- Ethics & Leadership
- AI Modeling Healthcare
- Healthcare IT
- Intellectual Property
- Disputes & Settlements
- Intellectual Property, Innovations, Commercialization, Investment in Technological Breakthroughs
- Drug Development Process
- Pharmacovigilance
- Venture Capital
BIO
John LaHaye
Business Strategy Consultant/Advisor
Compassionate Transformational Leader
(973) 477-9703 | lahaye.john@gmail.com | www.linkedin.com/in/jlahaye
johnlahaye@protonmail.com
Profile Summary
Business Strategy Executive/Consultant/Advisor with proven track record of success in delivering global strategic and financial growth objectives with public and PE/VC portfolio companies in Life Sciences, Biopharma, and High Tech Enterprise industries. Leverages exemplary leadership, organizational, and communication skills to maximize companies’ profitability and efficiency, while maintaining industry-leading standards of excellence.
Areas of Expertise
|
Professional experience
GLOBAL BUSINESS DEVELOPMENT CONSULTING GROUP
North Carolina
Business Strategy Consultant/Advisor – Contract and Full Time Engagements
2020 – Present
- Served as independent consultant advising private equity and venture-capital-backed companies on commercial strategic initiatives.
- Conceptualized and implemented innovative revenue growth initiatives with existing and new customers.
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE, (LPBI) Group
Newton, MA
Member Business Advisory Board, Business Development CRO economic segment
February 2024 – Present
See roles at LPBI Group, above
BioPulse CONSULTING, Channel methods partners, AIZON
Business Strategy Consultant – Contract Based
2023 – Present
CAMBREX
North Carolina
Head of Commercial Strategy and Operations, Drug Development and Testing
2021 – 2022
PERMIRA Portfolio Company, Cambrex | Permira
Accomplishments:
- Established commercial operations strategic initiatives for Drug Development and Testing (DDT) $100M Business Unit.
- Improved costing, pricing, proposal, and contract management standards. Delivered 20% CAGR over 18 months.
BUSHU PHARMA
Saitama, Japan
Head of US/EU Commercial Strategy – Contract Based
2021
Baring Private Equity Asia (BPEA) Portfolio Company, BPEA | Private Equity | Portfolio (bpeasia.com)
- Developed and launched Gateway to Asia services concept to optimize supply chain in APAC.
TERGUS PHARMA
North Carolina
Head of Global Commercial Strategy – Contract Based
2020 – 2021
Great Point Partner (GPP) Portfolio Company, Private Equity Portfolio – Great Point Partners (gppfunds.com)
- Managed New Business sales and marketing to effectively promote specialty pharma-contract research/development and manufacturing organization (CRO/CDMO) in Topicals.
- Implemented Quote/Proposal/Pricing/Costing functional group and Contract Management department.
THERMO FISHER SCIENTIFIC – Publicly Traded Company NYSE: TMO
PHARMA SERVICES GROUP (PSG)
North Carolina
PSG Global Strategic Account Leader
2018 – 2020
- Served as member of team of three executives managing nine global strategic accounts with revenue in excess of $2.4B for Thermo Fisher/$1.3B for Pharma Services Group (pSG).
- Held responsibility for client P&L and new business strategic initiatives.
- Negotiated a five-year Master Services Agreement with Total Contract Value (TCV) of $1B for one global strategic account.
- Formed corporate partnerships/joint governance committees, and instituted Customer Excellence programs.
PATHEON
North Carolina
Vice President, Global Business Development
2015 – 2018
JLL Partners Portfolio Company, Patheon | jll-partners
- Served as Head of Global Contract Management, Quote/Proposal/Pricing Services Group for New Business Sales for industry leading $3B Contract Development and Manufacturing Outsourcing (CDMO) firm.
- Managed development and delivery of 1,800 new business sales quotes/proposals amounting $3.6B in FY17.
- KpI’s: 95% On Time Delivery (OTD), 30% reduction in Cycle Time (CT), and Win Rate of 25%.
- Implemented contract management database system with over 1,100 active client agreements.
- Directed Quote to Win (QTW) corporate strategic initiative to improve key performance metrics, drive change management, and achieve continuous improvement/sustainability with business process owners.
GLOBAL BUSINESS DEVELOPMENT CONSULTING GROUP
New Jersey
Business Strategy Consultant/Advisor – Contract Based
2014 – 2015
- Served as independent consultant advising private equity and venture-capital-backed companies on sales and commercial strategies.
- Conceptualized and implemented innovative revenue growth initiatives with existing and new customers.
- Structured, negotiated, and executed complex solution-oriented commercial transactions.
- Designed sales incentive compensation plans for business development functions, resulting in high-performing teams.
CHOICE LOGISTICS, INC – Privately Owned Company New York
Senior Vice President, Account Management and Business Development
2011 – 2014
- Served as head of account services/management, business development, and marketing for leading solutions provider of service supply chain logistics aimed at high-tech equipment manufacturers (OEMs).
- Developed strategic growth Initiatives for business to reach $100M in revenue and $10M EBITDA.
- Led Customer Excellence program to revamp management of strategic accounts.
- Grew FY11 and FY12 revenue +10% and EBITDA +40% Y/Y.
CATALENT PHARMA SOLUTIONS – Publicly Traded Company NYSE: CTLT
New Jersey
Senior Vice President, Account Management and Business Development
2009 – 2011
- Served as head of account management, business development and marketing for the $160M Packaging Services division; part of the Medication Delivery Solutions (MDS) Business Unit.
- Restructured the account assignments and sales territories in US and Europe based on market segmentation
- Led the development and implementation of the Strategic Growth Plan for the Business Unit w/McKinsey and Co.
- Implemented a Customer Excellence and Innovation program w/ZS Associates, Inc. to include; customer contracting process, strategic sales, sales competencies model and customer experience team.
- Trained and deployed Miller Heiman and SPIN Strategic Selling methodologies.
- Managed Operations Excellence and Value Pricing initiatives to deliver profit +45% over target.
Additional experience
GLOBAL SAFETY SURVEILLANCE, INC., D/B/A SENTRX
New Jersey
Executive Vice President, Strategic Alliances and Business Development
2002 – 2009
Edison Partners Portfolio Company, Portfolio | Edison Partners
Served as head of strategic partners, sales, and marketing for Edison Venture Portfolio Company, providing drug safety outsourcing services solutions (SaaS) to pharmaceutical and medical devices industries.
Advisory Board Member.
INNAPHASE CORPORATION, INC
Pennsylvania
President
2001 – 2002
Edison Partners Portfolio Company, Portfolio | Edison Partners
Led software firm which provided Laboratory Information Management Software (LIMS) solutions to global biopharmaceutical research organizations.
Negotiated and finalized the acquisition term sheet of InnaPhase by Thermo Fisher Scientific.
DENDRITE INTERNATIONAL, INC – Publicly Traded Company NYSE: DRTE
New Jersey
President – SalesPlus Division
1999 – 2001
Led mid-tier division of Dendrite as result of board-approved Cornet acquisition. Developed and executed integration plan, including identification of synergies and growing revenue in targeted market segment.
Senior Vice President, Corporate Development
1996 – 1999
Served as head of Mergers & Acquisitions (M&A) department as well as Advisory Board Member.
Vice President, Software Development and Technical Services
1993 – 1996
Served as head of Software Product Development. Instrumental in bringing the company public (IPO) in June 1995.
Group Business Director
1990 – 1993
Edison Partners Portfolio Company, Portfolio | Edison Partners
Managed strategic accounts and worldwide implementations of Sales Territory Management software across large pharmaceutical customers.
AMERICAN CYANAMID, INC – Publicly Traded Company NYSE: ACY
New Jersey
Business Director
1986 – 1990
Managed global strategic materials sourcing initiatives for the pharmaceuticals and medical devices divisions.
EDUCATION
Montreal University polytechnic Institute • Montreal
BSc. • Engineering, Operations Research & International Business
PROFESSIONAL DEVELOPMENT
- Executive Development Program – York University Business Graduate Program, Toronto
- Executive Development Program – McGill Graduate School of Business, Montreal
2012pharmaceutical
sjwilliamspa